Exclusive enteral nutrition initiates individual protective microbiome changes to induce remission in pediatric Crohn's disease

Deborah Häcker,Kolja Siebert,Byron J Smith,Nikolai Köhler,Alessandra Riva,Aritra Mahapatra,Helena Heimes,Jiatong Nie,Amira Metwaly,Hannes Hölz,Quirin Manz,Federica De Zen,Jeannine Heetmeyer,Katharina Socas,Giang Le Thi,Chen Meng,Karin Kleigrewe,Josch K Pauling,Klaus Neuhaus,Markus List,Katherine S Pollard,Tobias Schwerd,Dirk Haller
DOI: https://doi.org/10.1016/j.chom.2024.10.001
2024-11-13
Abstract:Exclusive enteral nutrition (EEN) is a first-line therapy for pediatric Crohn's disease (CD), but protective mechanisms remain unknown. We established a prospective pediatric cohort to characterize the function of fecal microbiota and metabolite changes of treatment-naive CD patients in response to EEN (German Clinical Trials DRKS00013306). Integrated multi-omics analysis identified network clusters from individually variable microbiome profiles, with Lachnospiraceae and medium-chain fatty acids as protective features. Bioorthogonal non-canonical amino acid tagging selectively identified bacterial species in response to medium-chain fatty acids. Metagenomic analysis identified high strain-level dynamics in response to EEN. Functional changes in diet-exposed fecal microbiota were further validated using gut chemostat cultures and microbiota transfer into germ-free Il10-deficient mice. Dietary model conditions induced individual patient-specific strain signatures to prevent or cause inflammatory bowel disease (IBD)-like inflammation in gnotobiotic mice. Hence, we provide evidence that EEN therapy operates through explicit functional changes of temporally and individually variable microbiome profiles.
What problem does this paper attempt to address?